USE FOR INTERLEUKIN-33 (IL-33) AND THE IL-33 RECEPTOR COMPLEX

(19)

(11)

EP 2 283 860 A3

(12)	EUROPEAN PATENT APPLICATION

(88)	Date of publication A3:
	05.06.2013 Bulletin 2013/23

(43)	Date of publication A2:
	16.02.2011 Bulletin 2011/07

(21)	Application number: 10177117.8

(22)	Date of filing: 15.02.2005

(51)

International Patent Classification (IPC):

A61K 39/395^(2006.01)
A61K 38/17^(2006.01)
A61P 19/02^(2006.01)
A61P 31/00^(2006.01)
A61P 37/00^(2006.01)
C07K 14/715^(2006.01)
C07K 16/28^(2006.01)

A61K 38/20^(2006.01)
A61P 11/06^(2006.01)
A61P 25/02^(2006.01)
A61P 35/00^(2006.01)
C07K 14/54^(2006.01)
C07K 16/24^(2006.01)
A61K 38/00^(2006.01)

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR
	Designated Extension States:
	AL BA HR LV MK YU

(30)

Priority:

17.02.2004 US 545730 P

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	05713577.4 / 1725261

(71)	Applicant: Merck Sharp & Dohme Corp.
	Rahway, NJ 07065-0907 (US)

(72)	Inventors:
	Schmitz, Jochen Palo Alto, CA 94306 (US) Oft, Martin Palo Alto, CA 94301 (US) Kastelein, Robert, A. Redwood City, CA 94062 (US) Bazan, J. Fernando Menlo Park, CA 94025 (US)

(74)	Representative: Miller, David James
	Mathys & Squire LLP 120 Holborn London EC1N 2SQ London EC1N 2SQ (GB)

(54)	USE FOR INTERLEUKIN-33 (IL-33) AND THE IL-33 RECEPTOR COMPLEX

(57) Provided are methods of modulating cytokine activity, e.g., for the purpose of treating immune and inflammatory disorders, including tumors and cancer. Also provided are methods of administering agonists or antagonists of IL-33 and IL-33 receptor.

Search report

Search report